Twenty-six HIV positive patients were included in the study. Sixteen patients were treated with fluvoxamine 100-150 mg/die p.o. t.i.d. and 10 patients were treated with placebo for 8 weeks under double-blind conditions. Patients treated with fluvoxamine showed a significant HAM-D improvement (p <0.01). Eleven of the 26 patients died within a year of the end of the trial. They showed a higher T0 and T8 HAM-D total score compared to the surviving patients with a significantly higher T8 HAM-D score (p <0.01) in patients treated with placebo.
|Number of pages||3|
|Publication status||Published - 1994|
- HIV+ patients
ASJC Scopus subject areas
- Psychiatry and Mental health